Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARAGON-HF
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 13 Nov 2023 Results assessing the association between the number of echocardiographic RVD parameters and clinical outcomes, presented at the American Heart Association Scientific Sessions 2023.
- 13 Nov 2023 Results of cost-effectiveness analysis of sacubitril-valsartan in patients with HFmrEF/HFpEF , based on clinical event rates were based on 5-year data from the I-PRESERVE and event rates observed in the pooled analysis of the PARAGON-HF and PARAGLIDE-HF , presented at the American Heart Association Scientific Sessions 2023